Lombard Odier Asset Management Switzerland SA Has $12.27 Million Holdings in Amgen Inc. $AMGN

Lombard Odier Asset Management Switzerland SA boosted its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 21.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 37,472 shares of the medical research company’s stock after buying an additional 6,611 shares during the period. Lombard Odier Asset Management Switzerland SA’s holdings in Amgen were worth $12,265,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of AMGN. Anfield Capital Management LLC raised its holdings in Amgen by 1,000.0% during the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after buying an additional 70 shares during the period. Dogwood Wealth Management LLC raised its stake in Amgen by 275.0% during the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 55 shares during the period. Board of the Pension Protection Fund acquired a new stake in Amgen during the 4th quarter valued at $26,000. Manning & Napier Advisors LLC raised its stake in Amgen by 49.2% during the 4th quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after purchasing an additional 32 shares during the period. Finally, Olistico Wealth LLC acquired a new position in shares of Amgen in the 4th quarter valued at about $33,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction on Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the transaction, the senior vice president directly owned 7,009 shares of the company’s stock, valued at $2,269,023.57. This represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 0.85% of the stock is owned by insiders.

Amgen Trading Down 0.8%

NASDAQ:AMGN opened at $347.84 on Wednesday. The stock’s 50 day moving average price is $341.02 and its 200 day moving average price is $345.89. Amgen Inc. has a 52 week low of $267.83 and a 52 week high of $391.29. The company has a market capitalization of $187.73 billion, a P/E ratio of 24.21, a P/E/G ratio of 3.52 and a beta of 0.42. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. The firm had revenue of $8.62 billion for the quarter, compared to the consensus estimate of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The firm’s revenue was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, research analysts forecast that Amgen Inc. will post 22.38 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. Mizuho upped their target price on Amgen from $295.00 to $303.00 and gave the company a “neutral” rating in a report on Tuesday. Piper Sandler reiterated an “overweight” rating on shares of Amgen in a report on Friday. Canaccord Genuity Group began coverage on shares of Amgen in a research note on Monday, April 20th. They issued a “hold” rating and a $366.00 price target on the stock. Royal Bank Of Canada upped their price target on shares of Amgen from $360.00 to $370.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 7th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $350.00 price target on shares of Amgen in a research note on Wednesday, April 8th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, fifteen have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, Amgen presently has an average rating of “Hold” and a consensus target price of $354.42.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.